摘要
在过去10年中,晚期卵巢癌的新辅助化疗和间隔减瘤术一直是人们关注的焦点,全文回顾了近年来的有关文献,认为对于那些预计首次手术无法切除的晚期卵巢癌,由于缺乏随机对照研究证实新辅助化疗能够改善生存,尚不能作为常规治疗手段来使用。同时,探讨了欧洲和美国的两项有关卵巢癌间隔减瘤术的随机对照研究。
In the last decade,the value of neoadjuvant chemotherapy and interval debulking surgery in the management of advanced epithelial ovarian cancer has been widely debated.Various studies in the past few years are reviewed in this article.Because superior survival has not yet been demonstrated in a prospective randomized study,general acceptance of neoadjuvant chemotherapy as an alternative to primary surgery for patients who are not ideal surgical candidates remains limited.Two randomized studies about interval debulking surgery of ovarian cancer from Europe and America are discussed.
出处
《肿瘤学杂志》
CAS
2003年第2期63-64,共2页
Journal of Chinese Oncology
关键词
卵巢癌
化疗
间隔减瘤术
晚期
上皮性
ovarian neoplasms
neoadjuvant chemotherapy
interval debulking surgery
